A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
← catalyst calendarNCT07064122 · readout in 793 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
72estimated
Sites
21
Countries
Australia, Japan, South Korea +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-03 | actual | When the study began enrolling |
| Primary completion | 2028-10-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-20 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Haematologic Neoplasms
Intervention
- Drug: AZD2962
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose limiting toxicity (DLT)
measured From Cycle 1 Day 1 up to end of Cycle 1 (28 Days)
Number of participants with Adverse events (AEs) and serious AEs
measured Cycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)
Duration of exposure
measured Cycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)
Relative dose intensity
measured Cycle 1 Day 1 up to safety follow-up (30 days after last dose) (Approximately 3 years)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed